Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | MET | P08581 | 1/20 | 0.68 |
| ▸ | HCK | P08631 | 1/20 | 0.68 |
| ▸ | SRC | P12931 | 1/20 | 0.68 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.68 |
| ▸ | AXL | P30530 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779503 | 1.00 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL2072074 | 1.00 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL436189 | 1.00 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL29838794 | 1.00 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL5375309 | 0.91 | EGFR (0.64) | EGFRERBB2ERBB4SRC | |
| SCHEMBL4060171 | 0.91 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL5425627 | 0.91 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL17498539 | 0.89 | EGFR (0.74) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL29043124 | 0.88 | EGFR (0.73) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL12525787 | 0.88 | EGFR (0.57) | EGFRERBB2ABL1RETERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508521-B2 | Method for the production of amino crotonyl compounds | BOEHRINGER INGELHEIM INT (DE) | 2022-09-07 | — | — | EP | disclosed |
| EP-3089976-B1 | CRYSTALLINE FORMS OF AFATINIB DIMALEATE | TEVA PHARMACEUTICALS INT GMBH (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-9630952-B2 | Crystalline forms of afatinib di-maleate | IVAX International GmbH (CH) | 2017-04-25 | — | — | US | disclosed |
| EP-3089976-A1 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE | Teva Pharmaceuticals International GmbH (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-20160122329-A1 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE | IVAX International GmbH (CH) | 2016-05-05 | — | — | US | disclosed |
| EP-2508521-B1 | Dimaleat of an amino crotonyl compound and method of production thereof | BOEHRINGER INGELHEIM INT (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2015103456-A1 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2015-07-09 | — | — | WO | disclosed |
| EP-2826480-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | Boehringer Ingelheim International GmbH (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-20140057898-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20070185081-A1 | Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7223749-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1597240-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050159436-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-21 | — | — | US | disclosed |
| US-20050107358-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | disclosed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1499619-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004074263-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-02 | — | — | WO | disclosed |
| US-20040044014-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | US | disclosed |
| WO-2003089439-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057898-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BAX, BCL2, VEGFA | EGFR 498/4885ERBB2 2106/4885ABL1 1097/4885 |
| US-20050107358-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, AR, CYP11B1 | EGFR 404/4885ERBB2 225/4885ABL1 431/4885 |
| US-20050159436-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | RET, CYP11B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 478/4885ERBB2 329/4885ABL1 697/4885 |
| US-20070185081-A1 | Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, AR, RB1 | EGFR 263/4885ERBB2 140/4885ABL1 340/4885 |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BAX, BCL2, VEGFA | EGFR 498/4885ERBB2 2106/4885ABL1 1097/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | EGFR 584/4885ERBB2 2146/4885ABL1 1053/4885 |
| US-20160122329-A1 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE | CDC73, MET, TP53 | EGFR 8/4885ERBB2 22/4885ABL1 19/4885 |
| US-20040044014-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | CYP11B1, CYP11B2, AR | EGFR 309/4885ERBB2 208/4885ABL1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.